Nuvation Bio (NYSE:NUVB) executives said the company made continued commercial progress with ROS1-positive non-small cell lung cancer (NSCLC) therapy Ibtrozi during the first quarter of 2026, pointing to steady new patient demand, a shifting mix toward first-line use, and rising product revenue as m